Targeted drug combo for elderly DLBCL patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of targeted drugs (Obutinib or Decitabine) with standard chemo (Rituximab, Cyclophosphamide, Prednisone) for elderly patients with newly diagnosed diffuse large B-cell lymphoma who cannot handle full-dose chemotherapy. The goal is to see if this approach is safer and works as well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older and cannot tolerate standard chemotherapy.
- You have newly diagnosed diffuse large B-cell lymphoma confirmed by biopsy.
- Your overall health is fairly good (ECOG 0 or 1) and your IPI score is 3 or less.
- Your blood counts are adequate (neutrophils, platelets, hemoglobin) and your liver and kidney function are within safe limits.
- You have at least one tumor that can be measured on a scan (like a CT or PET).
- You must not have active hepatitis B, hepatitis C, HIV, CMV, syphilis, or serious infections, and no major heart, lung, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
This trial tests a lower-dose combination of chemotherapy drugs (R-mini-MCOP) for people aged 80 or older who have just been diagnosed with a common type of lymphoma called DLBCL. The goal is to see if this gentler approach is effective and easier to tolerate.
This study tests a “mini-CHOP-like” chemotherapy plan for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in people age 70 and older. It may help you learn whether this gentler regimen works well and is safe in older adults who are newly starting treatment.
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
Hear when a new Newly Diagnosed Diffuse Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.